ESMO Welcomes the Adoption of the 2017 WHO Cancer Resolution

Food and Healthcare Press Releases Friday June 2, 2017 09:02
LUGANO, Switzerland--2 Jun--PRNewswire/InfoQuest

ESMO, the leading European professional organisation for medical oncology, welcomes the adoption of the Resolution on Cancer prevention and control in the context of an integrated approach [http://apps.who.int/gb/ebwha/pdf_files/WHA70/A70_ACONF9-en.pdf ]   during the 70th World Health Assembly (WHA), 22-31 May, Geneva, Switzerland.

ESMO President Fortunato Ciardiello said "ESMO welcomes the WHO resolution that aims to ensure access to safe, effective and affordable care for cancer patients. Sustainability of cancer care is one of the three pillars of the ESMO 2020 Vision. As medical oncologists treating cancer patients, we strongly advocate for equal access to quality treatment. Our support to the stakeholders involved in this landmark WHO Resolution is a clear sign of ESMO's pledge towards a world where cancer patients are taken care of by highly specialised professionals."

"The last WHO Cancer Resolution dates back to 2005 [http://www.who.int/ipcs/publications/wha/cancer_resolution.pdf?ua=1]. ESMO has been working with the WHO for many years to improve cancer care," Ciardiello added. "It is crucial that with the number of new cancer cases rising, and over 14 million new cases being diagnosed worldwide every year [http://www.who.int/mediacentre/factsheets/fs297/en], there is a global and joint effort not only to prevent cancer, but also to ensure that those affected by the disease get optimal treatment and care, wherever they live, whatever their economic conditions are."

The 2017 WHO Cancer Resolution calls for national cancer control plans, high quality cancer registries, increased cancer research, use of clinical practice guidelines, timely access to medicines, medical devices and palliative care, as well as a well-trained oncology workforce. "ESMO is active in all these areas and committed to providing quality information, resources and the best education for cancer professionals," stated Ciardiello.

Full story: http://bit.ly/2qxxbNH
ESMO Press Office
media@esmo.org
+41(0)91-973-19-07
Source: European Society for Medical Oncology (ESMO)

Latest Press Release

ESMO Publishes New Position Paper on Supportive and Palliative Care

ESMO, the leading professional organisation for medical oncology, published a position paper on supportive and palliative care [ https://doi.org/10.1093/annonc/mdx757 ], calling attention to the evolving and growing gap between the needs of cancer...

Koch Disruptive Technologies to Lead $150 Million Investment of INSIGHTEC

The medical device company is transforming neurological treatments through its non-invasive focused ultrasound applications Koch Disruptive Technologies, a subsidiary of Koch Industries focused on finding and funding innovative and emerging companies,...

MediaTek Sensio: New Biosensor Solution Brings Health Monitoring to Smartphones

MediaTek Inc. today unveiled MediaTek Sensio(TM), the first 6-in-1 smartphone biosensor module. MediaTek Sensio is a powerful advanced health monitoring solution which makes it easy to track heart rate information, blood pressure trends, peripheral...

Merck Signs Distribution Agreement with Avanti(R) Polar Lipids

Merck , a leading science and technology company, today announced that it has entered into an agreement with Avanti(R) Polar Lipids to be the exclusive multinational distributor of the USA-based company's research lipids portfolio outside of the United...

Xultophy(R) Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

Newly published data from real-world European clinical practice has shown that Xultophy(R) (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes after six months.[1] The study looked at people with type 2...

Related Topics